408 results about "Mucus" patented technology

The heating apparatus for removing mucus comprises a face mask and a chest cover. The face mask may be adapted to be worn adjacent to a face and may retain water between the face mask and the face. The chest cover may be adapted to be worn adjacent to a chest and may retain water between the chest cover and the chest. The face mask and the chest cover may heat when activated and may be adapted to evaporate water to create water vapor which may help to break up mucus located within the user's sinuses and throat. The temperature of the heat created by the face mask and the chest cover may be controlled via a first thermostat control and a second thermostat control, respectively.

This invention relates to the technical field of deep processing of sturgeon by-products, and particularly to a sturgeon tendon peptide with antioxidant and pancreatic lipase inhibitory activities and its preparation method. The preparation method includes the following steps: mixing sturgeon with water and crushing it to form a first slurry; adding Bacillus licheniformis alkaline protease to the first slurry for a first hydrolysis; adding Bacillus subtilis neutral protease to the first hydrolysate for a second hydrolysis; adding a complex enzyme to the second hydrolysate for a third hydrolysis to obtain a sturgeon tendon hydrolysate; filtering the sturgeon tendon hydrolysate to remove impurities to obtain a filtrate, which is then filtered again to retain polypeptides, thus obtaining the sturgeon tendon peptide; wherein the complex enzyme includes pectinase and amylase. Using this method, a sturgeon tendon peptide with high glycosaminoglycan content can be obtained, which exhibits pancreatic lipase inhibitory activity, antioxidant activity, Staphylococcus aureus inhibitory activity, and prebiotic effects that promote the proliferation of Lactobacillus plantarum and Lactobacillus fermentum.

The invention relates to lactobacillus reuteri HC1602 as well as a fungicide and application thereof, and belongs to the technical field of microorganisms. The lactobacillus reuteri HC1602 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.26890, the preservation date is March 23, 2023, and the address of the preservation institution is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The invention further provides application of the lactobacillus reuteri HC1602 in preparation of products for inhibiting and preventing respiratory syncytial viruses and application of the lactobacillus reuteri HC1602 in preparation of products for reducing cholesterol in blood. The lactobacillus reuteri HC1602 provided by the invention can be used for effectively inhibiting the invasion of RSV (Respiratory Syndrome Virus) to A549 lung cells and improving the survival rate of the A549 cells.

The invention provides a probiotic composition for preventing and / or inhibiting oral pathogens as well as a derivative product, a preparation method and application of the probiotic composition, and belongs to the technical field of oral care. The probiotic composition comprises the following bacterial strains in parts by mass: 90 to 0.45 part of a lactobacillus rhamnosus bacterial strain A2114, 10 to 0.3 part of a plant lactobacillus bacterial strain A2124, 80 to 0.4 part of a pediococcus pentosaceus bacterial strain A2135, 250 to 0.25 part of a lactobacillus reuteri bacterial strain A21350, and 40 to 0.2 part of a plant lactobacillus bacterial strain A2109. The probiotic composition or the metabolite thereof can effectively inhibit oral pathogens such as streptococcus mutans, porphyromonas gingivalis, helicobacter pylori, escherichia coli and staphylococcus aureus. Therefore, the probiotic composition or the metabolite thereof shows a good application prospect in the aspects of preventing and relieving oral problems such as decayed teeth, periodontitis and ozostomia.

The invention discloses a strain of lactobacillus fermentum LF-HF25 obtained by screening sour cucumber, which is preserved in the China Center for Type Culture Collection, the preservation number is CCTCC No.M20241566, the classification name is the lactobacillus fermentum LF-HF25, the preservation date is July 15, 2024, and the preservation address is Wuhan University, China. The lactobacillus fermentum LF-HF25 has the advantages that the preservation number is CCTCC No.M20241566, the classification name is the lactobacillus fermentum LF-HF25, the preservation date is July 15, 2024, and the preservation address is Wuhan University, China. The lactobacillus mucilaginosus LF-HF25 or the metabiotic microbial inoculum prepared from the lactobacillus mucilaginosus LF-HF25 has the functions of dispelling the effects of alcohol, protecting the liver, promoting digestion and nourishing the stomach, also has the effect of improving sleep, and has a wide application prospect.

Modular mucosal tissue bioreactors combined with bioartificial mucus provide a high-fidelity, medium-throughput platform for evaluating CF treatments and modeling host-pathogen biology, a stepping stone towards better options for HEMT-nonresponsive patients. Whole lung ex vivo Cystic Fibrosis model system allows for investigation of candidate CF therapies.

The invention belongs to the technical field of microbial fermentation, and discloses lactobacillus mucilaginosus and application thereof in preparation of a uric acid reducing preparation. The survival rate of the fermented lactobacillus mucus in simulated gastric juice with the pH value of 2.0 for 3 hours is greater than 92%, the survival rate in simulated intestinal juice environment containing 0.5% of cholate is greater than 86%, and the viability of the fermented lactobacillus mucus is obviously higher than that of a conventional strain; and the tea has the effects of reducing uric acid, resisting oxidation and inhibiting pathogenic bacteria. The xanthine oxidase inhibition rate of the natural medicinal and edible compound potion obtained by mixing and co-fermenting the strain and existing bacterial powder is greater than 77% (45% or more higher than that of an unfermented group), and the oxidation resistance after fermentation can be improved by 50% at the same time. The beverage is suitable for being drunk as a daily functional food for a long time, and provides a natural and healthy collaborative diet relieving scheme for patients with hyperuricemia and gout.

The present application relates to the technical field of traditional Chinese medicine, in particular to a kind of slimming traditional Chinese medicine composition and preparation method thereof.The present application uses the raw materials such as Buzha Leaf, hawthorn, lotus leaf, immature fruit of Chinese citron, magnolia officinalis, raphanus sativus, dried orange peel, pellitory, alisma orientalis and cassia obtusifolia, after decoction, lactic acid lactobacillus lactis CICC 6242 and royi mucous lactobacillus CICC 6121 are fermented with 0.4-0.8:1 ratio, then combined enzymolysis is carried out using ginger protease and snail protease, and then 15-25wt% ethanol is used for extraction, and the composition is endowed with excellent lipid-lowering and weight loss effect.

The invention discloses lactobacillus mucus YF28 and application thereof, and belongs to the technical field of microorganisms. The fermented lactobacillus mucus YF28 is separated from Hu sheep manure, is classified and named as the fermented lactobacillus mucus YF28, and has the preservation number of CCTCC (China Center For Type Culture Collection) NO: M 20252433. The fermented lactobacillus mucilaginosus YF28 has good tolerance in the gastrointestinal environment and can reach the intestinal tract to play a role. The bacterial strain has strong intestinal adhesion capacity, is easy to form a probiotic biological membrane, and is beneficial to intestinal health. The fermented lactobacillus mucus YF28 can promote peristalsis, enrich the abundance of Akkermansia bacteria and bacteriophage thereof, restore the water content of excrement to a normal level, and significantly promote intestinal health. The invention has an application prospect in the development of drugs or health-care foods with the function of relieving constipation and related gastrointestinal symptoms.

The invention provides a preparation method of a Witzia ciliaris IOB502 microbial inoculum and an application of the Witzia ciliaris IOB502 microbial inoculum in the aspect of recovering intestinal motility, the Witzia ciliaris IOB502 microbial inoculum is prepared by adopting a method of carrying out low-oxygen stress staged fermentation on chickpeas by adopting the Witzia ciliaris IOB502, and the generation of vitamins B1 and B2 can be promoted. The microbial inoculum does not affect physiological development of important organs such as liver, spleen and small intestine of mice, can improve defecation symptoms of the mice with constipation, increase defecation times and water content of excrement, improve intestinal movement of the mice with constipation, promote smooth passage of intestinal contents, effectively improve colon injury of the mice with constipation, and improve the constipation rate of the mice with constipation. Comprising mucous membrane layer thinning and mucus secretion reduction.

The invention belongs to the technical field of biological medicine, and particularly relates to eutectic gel, a preparation method thereof and application of the eutectic gel in promoting mucous membrane drug delivery. The invention provides eutectic gel. The eutectic gel comprises a eutectic solvent and a polymer solution, the eutectic solvent comprises a hydrogen bond acceptor and a hydrogen bond donor; the polymer solution is selected from one or more of a gelatin solution, a polyvinyl alcohol solution, a polyethylene solution or a pyrrolidone solution. The eutecticevaporate gel provided by the invention can realize rapid and tight adhesion and continuous administration on mucous membranes which continuously secrete mucus, and has the following advantages: tight adhesion can be formed on mucous membranes with dynamically updated mucus, so that the residence time of an administration system on the mucous membranes is prolonged; and a drug delivery channel is established by penetrating through a mucous layer, so that the drug is efficiently and continuously delivered to mucous membrane tissues. The deep eutectic gel effectively solves the problem that an existing mucous membrane drug delivery system is low in drug delivery efficiency.

The invention relates to lactobacillus mucilaginosus and application thereof in preparation of ginsenoside F4, and belongs to the technical field of biotransformation of traditional Chinese medicinal materials. The technical problems that in the prior art, a biotransformation technology of rare ginsenoside F4 is insufficient in selectivity and environmental friendliness and high in cost are solved. The lactobacillus mucus disclosed by the invention is classified and named as LA729; the lactobacillus mucus is preserved in the China Center for Type Culture Collection (CCTCC) on August 4, 2025, and the preservation number of the lactobacillus mucus is CCTCC NO: M 20251765. The strain is safe in source and free of toxic and side effects, can secrete specific glycosidase in the fermentation process and selectively hydrolyze sugar residues on ginsenoside Re, so that structural reconstruction of the ginsenoside Re is achieved, target rare ginsenoside F4 is generated, selectivity is high, by-products are few, and the yield is stable.

The invention discloses a Su semi-poria cocos-tangerine decoction for relieving high secretion of mucus in an acute exacerbation stage of chronic obstructive pulmonary disease as well as a preparation method and application of the Su semi-poria cocos-tangerine decoction, and relates to the technical field of traditional Chinese medicine compositions. The Su semi-poria cocos and orange soup is prepared from 8-10 g of fructus perillae, 8-10 g of rhizoma pinellinae praeparata, 8-10 g of ginger processed cortex magnoliae officinalis, 8-10 g of radix peucedani, 4-6 g of fried semen brassicae, 8-10 g of fried semen raphani, 8-10 g of fried rhizoma atractylodis macrocephalae, 12-15 g of poria cocos, 4-6 g of fried pericarpium citri reticulatae and 2-3 g of cortex cinnamomi. Clinical application of the Su semi-poria cocos and tangerine decoction prepared by the invention shows that compared with a control group which is only treated by conventional western medicine, the secretion amount of mucoprotein MUC5AC is greatly reduced, traditional Chinese medicine symptom integral, CAT score and mMRC score are greatly reduced, symptoms of a patient are obviously relieved, and no adverse reaction occurs. Therefore, the Su semi-poria cocos and orange soup can relieve high secretion of mucus with the syndrome of AECOPD turbid phlegm obstructing lung and improve clinical symptoms of patients, and is good in safety.

The invention relates to the technical field of water treatment, in particular to a magnetic biological flocculant, a preparation method of the magnetic biological flocculant and application of the magnetic biological flocculant in retention of emerging pollutants. According to the magnetic biological flocculant provided by the invention, an initial oxygen mineral on the earth is used as a body nano mineral, a binary wet ball milling method is adopted to prepare a sub-nano mixed mineral, then the sub-nano mixed mineral is subjected to ultrasonic treatment and solid-liquid separation, and then reduction roasting is performed to obtain a sub-nano zero-valent complex mineral; then, mixing the sub-nanometer zero-valent complex minerals with silicate minerals and lotus leaf powder, and embedding by using marine animal mucus, so as to prepare the magnetic biological flocculant. The surface of the magnetic biological flocculant is rich in a large number of hydroxyl functional groups, the reaction activity is high, marine animal mucus can be effectively prevented from going bad, and efficient retention of emerging pollutants is achieved. In addition, the magnetic biological flocculant is non-toxic and harmless, and the potential risk to the environment is eliminated.

The invention discloses a tea leaf theanine composition for protecting a central nervous system as well as a preparation method and application thereof, relates to the field of common foods and health-care foods, and aims to solve the problems that most of existing central nervous protection products are single components or are simply compounded, the synergistic effect is weak and the bioavailability is low. The preparation method comprises the following steps: S1, mixing the tea leaf theanine, the emblic leafflower fruit powder, the ginkgo leaf extract, the wolfberry fruit powder and other raw materials according to a specific ratio, and performing high-temperature sterilization and cooling to obtain a fermentation substrate; s2, inoculating a composite activation microbial inoculum composed of plant lactobacillus, lactobacillus acidophilus and lactobacillus reuteri, and carrying out constant-temperature anaerobic fermentation; and S3, freezing and centrifuging at 4 DEG C, concentrating with an RO membrane, and freezing and drying to obtain the composition. The viable count of the complex microbial inoculant reaches 2.0 * 10 < 9 >-3.0 * 10 < 9 > CFU / mL, and the strain ratio and the fermentation process are optimized. The composition has a synergistic effect of multiple components, can efficiently protect nervous centralis, and is suitable for preparing related common food, health food or functional food.

Devices, systems, and methods for high frequency chest wall oscillation (HFCWO) therapy can enhance expectoration by preferred impact to the user to encourage mucus dislodging, including by successive pressure imposition by a chest engagement device to provide HFCWO.

The invention belongs to the technical field of biochemistry, and particularly relates to a probiotic composition for relieving depression as well as a preparation method and application of the probiotic composition. The probiotic composition is prepared from bacillus cecum, lactobacillus reuteri and an oligosaccharide composition; wherein the viable count of the bacillus cecum and the lactobacillus reuteri is 10 < 9 >-10 < 11 > CFU / g; the oligosaccharide composition is prepared by compounding polydextrose, fructo-oligosaccharide and galactooligosaccharide according to an optimized weight ratio. According to the invention, the oligosaccharide composition is cooperated with the probiotics to play a curative effect, so that the proliferation effect of the bacteroides cecum and the lactobacillus reuteri in the intestinal tract is improved, and the balance of the probiotics in the intestinal tract is regulated. Detection results of behavioristics and physiological indexes of mice show that the depression-like behaviors of the mice are remarkably reduced under the action of the composition, and various biochemical indexes are remarkably improved; the composition has a certain improvement effect on depressive mood.

The invention relates to the technical field of biological medicine, in particular to a drug screening model construction method based on airway organs, a model and application. The construction method of the drug screening model of the airway organoid comprises the steps of obtaining 2D airway epithelial cells, culturing the airway organoid, establishing an airway organoid inflammation model and / or establishing an airway organoid mucus secretion / goblet cell metaplasia model. Wherein the model is established according to the culture mode of the airway organ in cooperation with a specific stimulant for proliferation and differentiation. Compared with a traditional animal model, the organ-like model is low in cost and short in construction period, can better simulate the pathological process, can realize airway organ-like culture and establishment of an inflammation model and a mucus secretion / goblet cell metaplasia model at the same time, and has a good application prospect in drug detection of asthma and COPD diseases.

The present invention relates to Akkermansia muciniphila Akk11 having the functions of regulating blood glucose and blood fat and the use thereof. Said Akkermansia muciniphila Akk11 is classified and named as Akkermansia muciniphila Akk11 with the accession number of CCTCC NO: M2024119. The strain uses mucin as the unique source of carbon element and nitrogen element, so as to control the basic regulatory systems of glucose and energy metabolism, protect the integrity of intestinal epithelial cells and mucus layers to exert a protective effect on metabolism, regulate the levels of blood glucose and blood fat, and remarkably relieve symptoms of metabolic disorders, and thus providing strategies and reference basis for the prevention and treatment of obesity.

The invention discloses a lactobacillus mucus fermentation strain. The microbial preservation number of the lactobacillus mucus fermentation strain is CCTCC (China Center for Type Culture Collection) NO: M 20252262. The strain can inhibit enterotoxigenic escherichia coli, and can treat or slow down diarrhea, intestinal oxidative damage, intestinal inflammation damage, intestinal morphological damage, intestinal barrier function damage and intestinal flora disorder caused by the enterotoxigenic escherichia coli. The strain is a probiotic with a clinical application prospect.

The invention belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to fermented lactobacillus mucus with an anti-aging function and application of the fermented lactobacillus mucus. The strain is preserved in Guangdong Microbial Culture Collection Center on August 27, 2025, and the preservation number is GDMCC No: 66877. Experimental results show that the bacterium has excellent oxidation resistance, can relieve oxidative damage, delay senescence and inhibit senescence-related gene expression, shows the capabilities of improving memory reproduction capability decline caused by senescence, improving body anti-inflammatory capability and improving intestinal flora imbalance induced by senescence, and can regulate fat factor level and improve energy metabolism, so that the function of resisting senescence is achieved. And the polypeptide shows the potential of resisting fat deposition and protecting liver functions. Therefore, the strain can be used for developing products with multiple beneficial functions of delaying senescence, contributing to resisting oxidation, assisting in improving memory, contributing to regulating intestinal flora and the like, has the advantages of high safety, strong gastrointestinal tract tolerance and good colonization ability, and has a very good application value.

The invention belongs to the technical field of biology, and particularly relates to a complex microbial inoculant for promoting formation of a biological membrane, a microcapsule and application of the complex microbial inoculant. The complex microbial inoculant comprises lactobacillus mucus fermentation FMBL L24016DMX with the preservation number of CCTCC NO: M20241583 and bifidobacterium longum subsp. Longum FMBL B241770LS with the preservation number of CCTCC NO: M 20241993, the complex microbial inoculant can grow on a culture medium containing prebiotics, the biofilm formation amount is the highest when the complex microbial inoculant is co-cultured in a culture medium containing isomaltooligosacharide, the complex microbial inoculant is prepared into a single-layer microcapsule or a double-layer microcapsule, and the complex microbial inoculant can be used for preparing the probiotics. The endophytic fungus has good embedding rate and viable count, can resist gastrointestinal environment, has good heat resistance, and has wide application prospects.

The invention belongs to the field of medicines, and particularly relates to application of a cough relieving agent in preparation of an anti-influenza virus medicine. Through the synergistic effects of resisting viruses, resisting inflammation, regulating mucus secretion and inhibiting nerve sensitization, the antitussive agent relieves influenza symptoms and promotes recovery from the source, has the advantages of being stable in curative effect, small in toxic and side effect, not prone to generating drug resistance, not capable of promoting virus variation and the like, is wider in application stage and application crowd, and can intervene in the early stage of influenza infection. Due to the fact that the antitussive agent can treat influenza caused by exogenous cold and influenza viruses, the antitussive agent can be used in time to relieve symptoms when cough, excessive phlegm and other symptoms are found in the early stage of a patient, the antitussive agent can relieve the exogenous cold for a non-influenza patient, and the antitussive agent can prevent influenza from being converted into severe influenza from mild influenza for an influenza patient. And the reduction of the treatment effect caused by definite diagnosis delay and oseltamivir treatment delay is also avoided.

This invention discloses a quantitative detection kit for arginine peptidase, a qualitative detection kit for arginine peptidase, and their usage methods. The quantitative detection kit utilizes the specific substrate Nα-benzoyl-DL-arginine-4-ylbenzamide hydrochloride, which can be hydrolyzed by arginine peptidase to 4-ylbenzamide. 4-ylbenzamide has a maximum absorption peak at 405 nm, and the specific arginine peptidase activity can be rapidly detected at room temperature using spectrophotometry. The qualitative kit utilizes the specific substrate Nα-benzoyl-DL-arginine-β-naphthamide hydrochloride, which can be hydrolyzed by arginine peptidase to p-β-naphthamide. β-naphthamide combines with 4-(dimethylamino)cinnamaldehyde to form a compound that is visible to the naked eye as a pink color. The disulfide bond cleaving agent cuts the mucus disulfide bonds, exposing bacterial enzyme sites, and the synergistic effect of the enzyme activator enhances the reaction rate of arginine peptidase hydrolysis of the substrate, significantly improving the detection sensitivity of arginine peptidase in tongue coating samples.

The invention provides application of pinostrobin in preparation of a medicine for treating gastric ulcer, and belongs to the technical field of biological medicine. The pinostrobin provided by the invention realizes the anti-gastric ulcer effect by improving the gastric mucosa blood flow volume, inhibiting inflammatory reaction, inhibiting oxidation reaction and maintaining the integrity of the gastric mucus barrier. Pinostrobin can reduce the gastric ulcer area of rats and increase the pain threshold value; the content of ET-1 in plasma is reduced, and the repairing effect of gastric mucosa is enhanced; the contents of TNF-alpha and IL-6 are reduced, the content of IL-10 is increased, and the anti-inflammatory effect is enhanced; the content of T-SOD in plasma is increased, the content of MPO is reduced, and the antioxidant effect is enhanced. The pinostrobin is expected to be used as a new medicine for treating gastric ulcer.

The present invention addresses the problem of providing a composition for controlling bacteria belonging to the genus Fusobacterium among the intestinal flora. The present invention provides a composition for controlling a bacterium belonging to the genus Fusobacterium in the intestinal flora, the composition comprising a bacterium belonging to the family Lactobacillus. The bacterium belonging to the genus fusobacterium is preferably a fusobacterium nucleatum (fusobacterium nucleatum), and the bacterium belonging to the genus fusobacterium is preferably a fusobacterium nucleatum (fusobacterium nucleatum). It is preferable that the bacterium belonging to the family Lactobacillus belong to a bacterium belonging to any genus selected from the group consisting of the genus Lactobacillus, the genus Lactobacillus, the genus Limosilbacilli, the genus Liiilbacilli, the genus Lactobacillus lactis, the genus Lactobacillus casei, and the genus Lactobacillus plantarum, and that the bacterium belonging to the family Lactobacillus is a bacterium belonging to any genus selected from the group consisting of the genus Lactobacillus, the genus Lactobacillus lactis, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus and the genus Lactobacillus acidophilus.

The invention relates to the technical field of biological medicine, in particular to mussel mucin and hyaluronic acid cross-linked self-repairing eye health care cream and a 4D forming method thereof. The composition comprises stearic acid, cetostearyl alcohol and the like, a lactic acid bacteria fermentation extract, a jasmine flower extract, a wolfberry extract, a pseudo-ginseng extract, a cassia seed extract, a polygonum cuspidatum extract, a chrysanthemum extract, a leontopodium leontopodum extract, ethylparaben, methylparaben and the like, decapeptide-4, mussel mucin, proteoglycan protein and modified graphene. Modified graphene in the self-repairing eye health care cream can effectively promote crosslinking of mussel mucin and hyaluronic acid and improve the repairing effect, the micro-current effect of graphene can also promote skin tissue to absorb traditional Chinese medicine components and deeply repair eyes, the effect can be more obvious according to personal eye conditions and requirements, and the self-repairing eye health care cream has a good application prospect. The composition has the effects of relieving asthenopia, dryness and soreness, effectively delaying excessive growth of an ocular axis, relieving temporary myopia drift, relieving asthenopia and protecting near vision.

An application aid (10) suitable for assisting a user in applying an adhesive base plate (20) of an ostomy device to a skin surface around a user's stoma, the adhesive base plate including a first adhesive surface (30) facing the skin and a second surface (40) facing away from the skin, the application aid being configured to be removably attached to the base plate and adapted to at least partially surround the user's stoma during application of the base plate to the skin surface around the user's stoma, the application aid including a base portion (70) and a protective member (80) disposed on a surface of the base portion and adapted to prevent mucus from the stoma mucosa from contaminating the base plate during application of the base plate to the skin surface around the user's stoma.